The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib

2021 ◽  
Author(s):  
Ali Yılmaz ◽  
Melih Şimşek ◽  
Zekeriya Hannarici ◽  
Mehmet E Büyükbayram ◽  
Mehmet Bilici ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Prognostic Nutritional Index ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hcc ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio ◽  
Nutritional Index ◽  
Before And After ◽  
Immune Inflammation

Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan–Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin–bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin–bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.

Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma

2019 ◽  
Vol 13 (18) ◽  
pp. 1565-1575 ◽  
Author(s):  
Cem Mirili ◽  
Semra Paydas ◽  
Tuba Korkmaz Kapukaya ◽  
Ali Yılmaz
Keyword(s):  
Overall Survival ◽  
Hodgkin Lymphoma ◽  
Prognostic Nutritional Index ◽  
Progression Free Survival ◽  
Free Survival ◽  
Cox Regression Analysis ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Nutritional Index ◽  
Immune Inflammation

Aim: To evaluate the prognostic significance of neutrophil lymphocyte ratio, prognostic nutritional index, systemic immune-inflammation index (SII) and B2M in Hodgkin Lymphoma (HL). Materials & methods: Neutrophil–lymphocyte ratio, prognostic nutritional index, SII and B2M were analyzed to assess their prognostic value via the Kaplan–Meier method and Cox regression analysis in 122 HL patients, retrospectively. Results: SII was found to have the highest area under curve and the most sensitive and specific among all markers. In univariate analyses, all four parameters were prognostic for overall survival and progression-free survival, in multivariate analyzes only SII was found to be independent factors for both of them. Conclusion: SII can be suggested as a novel independent and better prognostic factor for predicting overall survival and progression-free survival in HL.

scholarly journals Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Are Respectively Associated with Prognosis of Gastric Cancer with Liver Metatasis Undergoing and without Hepatectomy

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Jialiang Gao ◽  
Yimin Wang ◽  
Fengke Li ◽  
Ziyu Zhu ◽  
Bangling Han ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Multivariate Analysis ◽  
Survival Rates ◽  
Prognostic Nutritional Index ◽  
Neutrophil To Lymphocyte Ratio ◽  
Prognosis Factor ◽  
Lymphocyte Ratio ◽  
Nutritional Index ◽  
Before And After ◽  
Prognostic Nutrition Index

Background. To clarify the efficacy of hepatectomy for gastric cancer liver metastasis (GCLM) and to investigate the association between prognostic nutrition index (PNI) or neutrophil-to-lymphocyte ratio (NLR) and prognosis of GCLM undergoing or without hepatectomy. Methods. We retrospectively studied 374 patients with GCLM. The ROC curve was used to determine the optimal cut-off of PNI and NLR. Patients were divided into groups based on whether hepatectomy was performed, and survival analysis was conducted before and after grouping. The overall survival (OS) time and 1, 3, 5-year survival rates were also compared. Results. Multivariate analysis of all GCLM patients revealed that hepatectomy (p=0.001) was an independent prognosis factor. And there were statistical differences in OS and 1, 3, 5-year survival rates (p=0.001 of all) between hepatectomy group and nonhepatectomy group. Multivariate analysis of GCLM undergoing hepatectomy showed that PNI was an independent prognosis factor (p=0.001). And there were statistical differences in OS and 1, 3, 5‐year survival rates (p=0.001p=0.005, p=0.001 and p=0.020, respectively) between high PNI group and low PNI group. Multivariate analysis of GCLM without hepatectomy showed that NLR was an independent prognosis factor (p=0.001). And there were statistical differences in OS and 1, 3, 5-year survival rates (p=0.001p=0.008p=0.031 and p=0.026, respectively) between low NLR group and high NLR group. Conclusions. GCLM has a better prognosis with hepatectomy. High preoperative PNI is a benign prognostic predictor for patients undergoing hepatectomy. And high preoperative NLR is an adverse prognostic factor for patients without hepatectomy.

Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio independently predict survival in resected small bowel adenocarcinoma.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 426-426
Author(s):  
Brandon M. Huffman ◽  
Shruti Patel ◽  
Siddhartha Yadav ◽  
Zhaohui Jin ◽  
Amit Mahipal
Keyword(s):  
Overall Survival ◽  
Multivariate Analysis ◽  
Small Bowel ◽  
Tumor Size ◽  
Neutrophil To Lymphocyte Ratio ◽  
Stage I ◽  
Small Bowel Adenocarcinoma ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio ◽  
Resected Small Bowel

426 Background: Small bowel adenocarcinoma is a rare malignancy affecting approximately 2,000 patients per year. There is a paucity of evidence prognosticating patients with small bowel adenocarcinoma. We aimed to evaluate multiple factors in patients with resected small bowel adenocarcinoma to determine any association with survival outcomes. Methods: Ninety three patients who underwent resection for stage I-III small bowel adenocarcinoma were retrospectively identified utilizing the pathology database at a single tertiary referral institution. All patients had complete follow up data and were included in the survival analysis. JMP software was used for statistical analysis. Overall survival was performed utilizing Kaplan-Meier method, and log-rank tests were used for statistical comparisons. Cox proportional hazards were performed to control for age, gender, location of tumor, tumor size, tumor stage, and adjuvant therapy. Sensitivity analysis was performed to establish best cutoff points for continuous variables. All tests were two sided and a P value of < 0.05 was considered significant. Results: The median age at diagnosis was 65 years (range 32-90). 61% were male. Median tumor size was 4.5 cm. There were 20, 36, and 37 patients with stage I, stage II, and stage III disease, respectively. Median overall survival (OS) was 151 months, 104 months, and 44 months for stages I, II, and III disease. In a multivariate analysis, independent predictor factors included presurgical lymphocyte to monocyte ratio (LMR) > 4.0, with a Hazard Ratio (HR) 0.13 (95% CI 0.007-0.69, p = 0.01), presurgical neutrophil to lymphocyte ratio (NLR) < 8.0, HR 0.39 (95% CI 0.17-0.96, p = 0.04), and tumor size < 7.5 cm, HR 0.22 (95% CI 0.07-0.85, p = 0.03). Stage, age, T stage, and N stage influenced overall survival in univariate analysis, but were not statistically significant on multivariate analysis. Conclusions: LMR and NLR independently predict survival in patients with resected small bowel adenocarcinoma.

scholarly journals Comparison of Systemic Immune-Inflammation Index (SII), Early Warning Score (ANDC) and Prognostic Nutritional Index (PNI) in Hospitalized Patients with Malignancy, and Their Influence on Mortality from COVID-19

2021 ◽  
Author(s):  
Muge Bilge ◽  
Isil Kibar Akilli ◽  
Aylia Yesilova ◽  
Kadriye Kart Yasar
Keyword(s):  
Early Warning ◽  
Prognostic Significance ◽  
Prognostic Nutritional Index ◽  
Biological Indicators ◽  
Early Warning Score ◽  
Hospital Death ◽  
Lymphocyte Ratio ◽  
Nutritional Index ◽  
Mortality Ratio ◽  
Immune Inflammation

Abstract Introduction: COVID-19 pandemic is a serious cause of increased mortality in patients having malignancy. Therefore, to help predict the clinical progression of those patients with COVID-19 who have multiple comorbidities as cancer, we need various indices whose parameters we can easily measure and rapidly calculate. We evaluated several biological indicators based on inflammation and/or nutritional status, such as systemic immune-inflammation index (SII), early warning score (ANDC) and prognostic nutritional index (PNI) in hospitalized COVID-19 patients with and without malignancies for a prognostic significance. Methodology: This is a retrospective and observational study on 186 patients with SARS-CoV-2, who were diagnosed with COVID-19 by real-time PCR testing and hospitalized due to COVID-19 pneumonia. 75 patients had various malignancies, and the rest (111), having a similar age and comorbidity profile based on propensity score matching, had no malignancy. Results: None of the measures as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (MLR), monocyte to lymphocyte ratio (PLR), SII, PNI or ANDC was found to be significantly different between two groups. Mortality ratio was found to be significantly higher in malignancy group (17,3%). Odds ratio for the mortality, OR:2,39 (%95 CI:1,80 -3,16) was found to be significantly higher for the malignancy group, even though the duration of hospitalization was statistically similar for both groups. PNI was found to be significantly lower for deceased patients compared with survivors in the malignancy group. Contrarily, ANDC was found to be significantly higher for deceased patients in the malignancy group. Conclusions: PNI and ANDC have independent predictive power on determining the in-hospital death in COVID-19 malignancy cases. It is suggested that ANDC seems to be a more sensitive score than SII in COVID-19 cases with malignancies.

scholarly journals Prognostic inflammatory markers in metastatic renal cell carcinoma: Neutrophil-to-lymphocyte ratio and prognostic nutritional index

2020 ◽  
Vol 7 (4) ◽  
pp. 459-465
Author(s):  
Mahmut Büyükşimsek ◽  
Ali Oğul
Keyword(s):  
Renal Cell Carcinoma ◽  
Risk Factor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Independent Risk Factor ◽  
Prognostic Nutritional Index ◽  
Neutrophil To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Nutritional Index

Objective: According to metastatic renal cell carcinoma treatment protocol, after the use of tyrosine kinase inhibitors (TKI) has been achieved significant improvements for the treatment of metastatic renal cell carcinoma (mRCC). In this study, we aimed to investigate the effect of neutrophil-to-lymphocyte ratio (NLR) and prognostic nutritional index (PNI) on survival in patients with mRCC treated with sunitinib or pazopanib. Material and Methods: Medical data for 38 patients with mRCC were reviewed retrospectively. NLR and PNI values were dichotomized based on receiver operating characteristic (ROC) curve analysis (cut-off values: 3 and 46, respectively). Univariate and multivariate analyses were performed to identify prognostic factors for progression free survival (PFS) and overall survival (OS) using a Cox proportional hazards model. Results: Median PFS and OS were 12 and 27 months, respectively. Median PFS was 10 months in patients with NLR ≥3 while 14 months in patients with NLR <3 (p: 0.008). Median OS was 18 months in patients with NLR ≥3 while 31 months in patients with NLR <3 (p: 0.003). In patients with PNI ≥ 46, PFS was 21 months and OS was 47 months whereas in patients with PNI < 46, PFS was 8 months and OS was 13 months (p values were <0.001, <0.001 respectively). In multivariate analysis, PNI was the independent risk factor for both PFS and OS, while NLR was the independent risk factor for OS only. Conclusion: In patients with mRCC that using sunitinib or pazopanib, NLR and PNI values can be used as easily accessible prognostic markers.

Sign in / Sign up

Export Citation Format

Share Document